Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The Suvar, Enhancer of zeste, and Trithorax (SET) and myeloid-Nervy-DEAF-1 (MYND) domain-containing protein 3 (SMYD3) is a histone lysine methyltransferase and has been recently unveiled to play significant roles in the progression of human cancer via regulating various key cancer-associated genes and pathways. The role of SMYD3 in gallbladder cancer (GBC) still needs to be studied. In the present study, we examined the SMYD3 gene expression at mRNA and protein level to look its impact on risk for developing gallbladder carcinogenesis. SMYD3 expression was evaluated by immunohistochemistry and reverse transcriptase PCR (RT-PCR) from 30 cases each of GBC and cholelithiasis patients. The expression was compared with different clinicopathological parameters. The SMYD3 expression was found to be significantly upregulated in GBC than cholelithiasis group ( < 0.05). The SMYD3 with increased expression level was observed in 73.3% of the GBC cases ( < 0.05). Moreover, mRNA SMYD3 expression was observed in 73.3% of GBC and 10% of control ( < 0.05). Our results indicated that the overexpression of SMYD3 plays an important role in the GBC progression, and SMYD3 may represent useful biomarker for gallbladder cancer patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8119546 | PMC |
| http://dx.doi.org/10.1007/s13193-020-01168-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lysine Methyltransferases SMYD2 and SMYD3: Emerging Targets in Kidney Diseases.
Kidney Dis (Basel)
July 2025
Department of Nephrology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Background: The SET and MYND domain-containing (SMYD) protein family is a group of lysine methyltransferases with SET and MYND domains and plays a critical role in regulating gene expression through the methylation of histone and non-histone proteins.
Summary: Studies have linked mutations or overexpression of SMYD2 and SMYD3 to various cancers, including renal carcinoma. Recent research also demonstrates that the expression levels and activity of SMYD2 and SMYD3 are increased in animal models of renal diseases such as autosomal dominant polycystic kidney disease, renal fibrosis, and diabetic nephropathy.
"Heptadecanol" a phytochemical multi-target inhibitor of SMYD3 & GFPT2 proteins in non-small cell lung cancer: an in-silico & in-vitro investigation.
J Comput Aided Mol Des
July 2025
Department of Life Sciences, School of Sciences, GSFC University, Vadodara, Gujarat, 391750, India.
Understanding the mechanism of action of anticancer agent plays a key role in effective clinical application of natural products. This study aims to identify an anti-cancer phytochemical with multi-target inhibition potential against non-small cell lung cancer. This study employs virtual screening of 8352 phytochemicals by molecular docking (AutoDock Vina & SeeSAR) to identify potential inhibitor of KRas, SMYD3, ALDH1 and GFPT2 proteins.
View Article and Find Full Text PDFBifaceted functions of histone methyltransferases.
Epigenomics
September 2025
Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.
In this perspective, Akhtar et al provide a brief overview of Enhancer of Zeste Homolog 2 (EZH2) and SET and MYND-domain containing 3 (SMYD3) as histone methyltransferases that function both as activators and repressors of gene transcription in cancer. The importance of deciphering the mechanisms underlying this bifaceted function toward thoughtful pharmacologic interventions is underlined and protein or mRNA degradation are highlighted as the most biologically rational pharmaceutical platforms to target these bifaceted histone methyltransferases.
View Article and Find Full Text PDFInvestigating SMYD3 role during oocyte maturation in a 3D follicle-enclosed oocyte model in sheep.
Front Cell Dev Biol
June 2025
Department of Bioscience and Technology for Food, Agriculture and Environment, University of Teramo, Teramo, Italy.
Background: SMYD3 is a histone methyltransferase known for its dual role in modifying both histone and non-histone proteins. Despite its established involvement in somatic cell function and oncogenesis, its role in mammalian oogenesis and early embryonic development remains unclear. This study aimed to elucidate the function of SMYD3 in regulating oocyte meiotic progression and developmental competence using sheep as a mono-ovulatory model.
View Article and Find Full Text PDFSmall molecule compound ZYZ-384 targets SMYD3 to alleviate aging.
Sci Rep
July 2025
State Key Laboratory of Quality Research in Chinese Medicine & Laboratory of Drug Discovery from Natural Resources and Industrialization, School of Pharmacy, Macau University of Science and Technology, Macau, China.
SMYD3 is a chromatin modifier that facilitates the trimethylation of histone 3 lysine 4 (H3K4) to induce diverse biological activities. We have provided a brief demonstration of the anti-aging effect of ZYZ-384, a newly developed inhibitor targeting SMYD3. In order to validate the anti-senescence effect of ZYZ-384, we utilized angiotensin II to induce senescence in two types of human endothelial cells (HMEC-1) and mouse endothelial cells (SVEC4-10), creating cellular models for senescence.
View Article and Find Full Text PDF